伊维菌素治疗新冠研究：综述

 伊维菌素治疗新冠研究：综述

1 帖子原文 Craig Kelly @CraigKellyPHON

https://x.com/CraigKellyPHON/status/1787226308596158649

AND ANOTHER : New Study, Ivermectin works again.

Double-blind randomised controlled study finds Ivermectin reduced ICU admissions by 83% (P <0.001)

Its time that those involved in denying sick and/or dying covid patients access to Ivermectin were arrested and charged with criminal negligence and crimes against humanity.

And don’t expect to find the results of this just published (April 30, 2024) study reported by the ABC or our corrupted MS Media. They’s rather cover-up these fundings than admit they were wrong. 

And what of all the poor simpletons that were so easily  propagandised, tricked into believing that Ivermectin was a horse paste ?  Will they apologise for their  stupidity & ignorance?    

https://brieflands.com/articles/jjhs-146703

Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial - Varnaseri et al., 

A double-blind, randomized clinical trial was conducted on 110 patients with moderate-to-severe (non-critical) confirmed COVID-19 infection. The patients were equally divided into two groups, with one group receiving ivermectin tablets (14 mg every 12 hours for three days) and the other group receiving a placebo.

Results: A total of 110 patients, including 62 (56.4%) men and 48 (43.6%) women, with an average age of 53.36 ± 15.10 years, were enrolled in our double-blind, randomized clinical trial. The baseline characteristics of the two groups were similar. The findings demonstrated that ivermectin significantly reduced the need for;

😀Intensive Care Unit admission (32.7% vs. 5.5%; P < 0.001),

😀hospitalization duration (six vs. four days; P < 0.001), and 

😀median time to symptom resolution period (P < 0.05) in COVID-19 patients compared to the placebo group, without any serious side effects (P > 0.05).

Based on our findings, ivermectin can be important in shortening the time to resolve symptoms such as fever, shivering, myalgia, cough, dyspnea, vomiting, and diarrhea. 

A recently conducted case series study has shown that combination therapy with doxycycline and ivermectin can also shorten the time to resolution for some symptoms related to COVID-19 infection in mild to moderate cases

  

These findings agree with those reported by Ahmed et al., who assessed the effects of a 5-day therapeutic regimen consisting of ivermectin on CRP and LDH levels, representing the severity of the inflammatory phase of the illness (23).

 In addition to its direct antiviral effect, this medication activates inhibitory pathways involved in the inflammatory process, such as TNF-alpha, interleukin-8, and LL-37. 

Subsequently, there is an indirect activation of interleukin-1 beta and interleukin-18, which results in a decrease in neutrophilic and eosinophilic chemotaxis and improvement in the signs and symptoms, shortening of the course of the illness, and faster resolution of abnormal laboratory findings.

Moreover, no serious adverse effects of this medication have been observed among the drug arm participants. 

Therefore, it seems this medication should be considered as a potential treatment for COVID-19 ……"

还有一项：新研究表明，伊维菌素再次发挥作用。

双盲随机对照研究发现伊维菌素使 ICU 入院人数减少了 83% (P <0.001)

是时候逮捕那些拒绝让生病和/或垂死的新冠患者获得伊维菌素的人了，并被指控犯有刑事过失和反人类罪。

并且不要指望找到 ABC 或我们腐败的 MS Media 报道的刚刚发表的（2024 年 4 月 30 日）研究的结果。他们宁愿掩盖这些资金，也不愿承认自己错了。

那么那些很容易被宣传、欺骗而相信伊维菌素是马膏的可怜的傻瓜呢？他们会为自己的愚蠢和无知道歉吗？

 https://brieflands.com/articles/jjhs-146703 

伊维菌素作为住院成人 COVID-19 患者的辅助治疗：一项随机多中心临床试验 - Varnaseri 等人，

对 110 名中度至重度（非危重）确诊的 COVID-19 感染患者进行了一项双盲、随机临床试验。患者被平均分为两组，一组接受伊维菌素片剂（每 12 小时 14 毫克，持续三天），另一组接受安慰剂。

结果：共有 110 名患者参加了我们的双盲随机临床试验，其中男性 62 名（56.4%），女性 48 名（43.6%），平均年龄 53.36 ± 15.10 岁。两组的基线特征相似。研究结果表明，伊维菌素显着减少了以下需求：

 😀 入住重症监护室（32.7% vs. 5.5%；P < 0.001），

 😀 住院时间（六天与四天；P < 0.001），以及

 😀 与安慰剂组相比，COVID-19 患者的症状缓解期中位时间 (P < 0.05)，且没有任何严重副作用 (P > 0.05)。

根据我们的研究结果，伊维菌素对于缩短缓解发烧、颤抖、肌痛、咳嗽、呼吸困难、呕吐和腹泻等症状的时间非常重要。

最近进行的一项病例系列研究表明，多西环素和伊维菌素联合治疗还可以缩短轻度至中度病例中与 COVID-19 感染相关的某些症状的解决时间

这些发现与 Ahmed 等人报道的一致，他们评估了由伊维菌素组成的 5 天治疗方案对 CRP 和 LDH 水平的影响，代表了疾病炎症阶段的严重程度 (23)。

 除了直接抗病毒作用外，该药物还能激活炎症过程中涉及的抑制途径，例如 TNF-α、白细胞介素 8 和 LL-37。

随后，间接激活白细胞介素 1β 和白细胞介素 18，导致中性粒细胞和嗜酸性粒细胞趋化性下降，改善体征和症状，缩短病程，并更快地解决异常实验室检查结果。

此外，在药物组参与者中没有观察到这种药物的严重副作用。

因此，看来这种药物应该被视为治疗 COVID-19 的潜在疗法……”

---

2  Gemini

伊维菌素治疗新冠研究：综述

摘要

一项新的研究表明，伊维菌素可以有效治疗新冠患者。该研究是一项双盲随机对照试验，对110名中度至重度新冠患者进行评估。结果表明，与差异组相比，伊维菌素组重症监护病房（ICU）的入院率、住院时间和症状缓解期中时间明显下降。此外，伊维菌素组没有发生任何严重后果。

研究方法

该研究对110名中度至重度新冠患者进行随机分配，一组接受伊维菌素治疗，另一组接受张力治疗。伊维菌素组患者每12小时服用14毫克伊维菌素，持续三天。 队伍由病人组成。

研究结果

研究结果表明，伊维菌素组重症监护病房（ICU）入院率显着下降。伊维菌素组ICU入院率为32.7%，而伊维菌素组重症组为5.5%（P < 0.001）。维菌素组的住院时间也明显长度，为 6 天，而结构组为 4 天 (P < 0.001)。此外，伊维菌素组的症状缓解期中位时间显着长度 (P < 0.05) 。

伊维菌素组没有任何严重的副作用。

结论

该研究表明，伊维菌素可以有效治疗新冠患者。伊维菌素可以降低 ICU 入院率、居民住院时间和热水器症状缓解期。伊维菌素安全耐受性良​​好。

重要声明

请注意，该研究是一项初步研究，需要考虑进一步研究来证实其结果。目前，伊维菌素尚未被美国食品药品管理局 (FDA) 批准用于治疗新冠。如果您正在使用伊维菌素治疗新冠，请务必咨询您的医生。

其他信息

该研究发表在《Jundishapur Journal of Health Sciences》杂志上。

参考文献

Varnaseri M、Amini F、Jamshididan R、Dargahi M、Gheibi N等。伊维菌素作为住院成人 COVID-19 患者的辅助治疗：一项随机多中心临床试验。 Jundishapur J 健康科学。 2024；16(2)：e146703。https://doi.org/10.5812/jjhs-146703

额外评论

该研究结果令人瞩目，但仍需进一步研究来证实其有效性和安全性。如果您正在考虑使用伊维菌治疗素新冠，请务必咨询您的医生。